Suvretta Capital Management, LLC Arcus Biosciences, Inc. Transaction History
Suvretta Capital Management, LLC
- $2.28 Billion
- Q1 2025
A detailed history of Suvretta Capital Management, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Suvretta Capital Management, LLC holds 2,560,904 shares of RCUS stock, worth $22.9 Million. This represents 0.88% of its overall portfolio holdings.
Number of Shares
2,560,904
Previous 576,156
344.48%
Holding current value
$22.9 Million
Previous $8.58 Million
134.36%
% of portfolio
0.88%
Previous 0.36%
Shares
5 transactions
Others Institutions Holding RCUS
# of Institutions
202Shares Held
63.1MCall Options Held
116KPut Options Held
116K-
Black Rock Inc. New York, NY9.76MShares$87.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.69MShares$59.8 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA5.13MShares$45.8 Million0.28% of portfolio
-
State Street Corp Boston, MA3.7MShares$33 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.87MShares$25.6 Million0.06% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $645M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...